Pharmac announces plan to fund cancer drugs Kadcyla and Alecensa
The national drug funding agency are proposing that by December 1 Kadcyla, for HER-2 positive metastatic breast cancer, and Alecensa for positive advanced non-small cell lung cancer will be made publicly available. A drug that treats relapsing remitting multiple sclerosis, known as Ocrevus, is also planned to be funded. They say they are seeking public feedback on the proposal to fund the three drugs by August 2019. All feedback received before the closing date will be considered by Pharmac's Board (or its delegate) prior to making the final decision on this proposal. This comes after a long-standing fight from advocacy groups and New Zealanders dying of cancer campaigning for the lives it could extend and save. Earlier this year Lung Cancer Foundation chief executive Philip Hope said five people die of the disease every day while a further six are diagnosed. It launched a petition calling for more and fairer funding from Pharmac, given the number of deaths caused by lung cancer each year. Hope said currently lung cancer drugs get $2,771,115.00 - or 2.3 per cent - of funding. More than 600 Kiwi women die each year from breast cancer, the nation's third most common form of cancer. Funding applications still pending include for Ibrutinib and Venetoclax for chronic lymphocytic leukaemia; Lenalidomide for multiple myeloma, an incurable blood cancer; for Lynparza and Avastin to be funded for ovarian cancer; six drugs for myeloma; Myozyme for late onset Pompe disease, a rare and fatal metabolic disorder; and medications including Keytruda, Osimertinib and Crizotinib for advanced lung cancer.
===========================================================
Some Choice News!
DOC is rolling out a new tool to help figure out what to tackle first when it comes to protecting our threatened species and the things putting them at risk.
Why does this matter? As Nikki Macdonald from The Post points out, we’re a country with around 4,400 threatened species. With limited time and funding, conservation has always meant making tough calls about what gets attention first.
For the first time, DOC has put real numbers around what it would take to do everything needed to properly safeguard our unique natural environment. The new BioInvest tool shows the scale of the challenge: 310,177 actions across 28,007 sites.
Now that we can see the full picture, it brings the big question into focus: how much do we, as Kiwis, truly value protecting nature — and what are we prepared to invest to make it happen?
We hope this brings a smile!
Poll: 🤖 What skills do you think give a CV the ultimate edge in a robot-filled workplace?
The Reserve Bank has shared some pretty blunt advice: there’s no such thing as a “safe” job anymore 🛟😑
Robots are stepping into repetitive roles in factories, plants and warehouses. AI is taking care of the admin tasks that once filled many mid-level office jobs.
We want to know: As the world evolves, what skills do you think give a CV the ultimate edge in a robot-filled workplace?
Want to read more? The Press has you covered!
-
52.6% Human-centred experience and communication
-
14.7% Critical thinking
-
29.9% Resilience and adaptability
-
2.7% Other - I will share below!
Share your favourite main crop potato recipe and win a copy of our mag!
Love potatoes? We will give away free copies of the May 2026 issue to readers whose potato recipes are used in our magazine. To be in the running, make sure you email your family's favourite way to enjoy potatoes: mailbox@nzgardener.co.nz, by March 1, 2026.
Loading…
